Medtech M&A Expected to Rebound in Second Half

The medical device industry saw a flurry of mergers and acquisitions in the first half of 2025, with deals exceeding $1 billion from companies like Stryker, Zimmer Biomet, and Thermo Fisher Scientific. However, activity has since slowed, with fewer billion-dollar transactions taking place after the first two months of the year.

Analysts noted that the slowdown in M&A activity is attributed to economic uncertainty and market fluctuations stemming from the Trump administration’s tariff policies. Companies became more cautious in their spending as questions arose about the impact of these policies on their businesses.

Despite the lull in dealmaking, experts anticipate that mergers and acquisitions will pick up in the second half of the year as the economic environment stabilizes. Companies are beginning to refocus on their long-term strategies, even amid lingering uncertainty surrounding tariff policies and other macroeconomic factors. Medtech firms are expected to increase spending in the second half of the year, with companies like Illumina, Boston Scientific, and Stryker showing interest in M&A activity. Areas of interest for acquisitions include surgical robotics, pulsed field ablation, structural heart, and diabetes. The industry is optimistic about future growth opportunities despite previous slowdowns.

Read more at Yahoo Finance: Will medtech M&A pick back up in the second half?